MISSION

• SpikImm is a Paris-based, clinical-stage biotech founded in 2021 by Truffle Capital in partnership with Institut Pasteur that develops monoclonal antibodies (mAbs) for the prevention of severe viral infections in transplant patients. 

• Transplant patients, who receive immunosuppressive therapy to prevent rejection, are very vulnerable to viral infections and often respond poorly to vaccines.

• When exposed to viruses such as SARS-CoV-2 and BK Virus (BKV), kidney transplant patients and hematopoietic stem cell transplant patients are at high risk of developing severe forms and complications of these infections.

• To address this major unmet need, SpikImm, is currently developing a unique portfolio of long-acting human mAbs targeting different viruses. These mAbs will provide a broad, immediate and long-lasting protection for transplant patients, improving transplant outcomes, patients’ prognosis and quality of life.

SCIENCE

MEDIA